恩度联合第3代含铂化疗方案治疗55例晚期非小细胞肺癌的临床观察  

Clinical observation on the efficacy of Endostar combined with platin-based chemotherapy for 55 cases of advanced non-small cell lung cancer

作　　者：龙建林[1] 李潞[1] 黄媚娟[1] 任莉[1] 侯梅[1] 王瑾[1] 徐泳[1] 彭枫[1] 卢铀[1] 

机构地区：[1]四川大学华西医院肿瘤中心胸部肿瘤科,成都610041

出　　处：《肿瘤》2010年第2期156-159,共4页Tumor

摘　　要：目的:观察重组人血管内皮抑制素恩度联合第3代含铂化疗方案治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效、中位无进展生存(progression-free survival,PFS)时间和不良反应。方法:55例晚期NSCLC患者接受恩度联合第3代含铂化疗方案治疗,化疗至少2个周期以上。观察指标包括PFS、总有效率(response rate,RR)、临床获益率(clinical benefit rate,CBR)和不良反应。结果:在51例可评价疗效的患者中,15例(29.4%)获得部分缓解,27例(52.9%)为疾病稳定,9例(17.6%)为疾病进展,无完全缓解患者;RR为29.4%(15/51),CBR为82.4%(42/51)。所有55例患者的中位PFS为6.3个月。不同病理类型(P=0.370)、初治与复治(P=0.101)、不同化疗方案(P=0.232)患者的近期疗效差异无统计学意义,PFS差异也无统计学意义。研究期间总的白细胞和血小板下降率分别为72.7%和54.5%,Ⅲ～Ⅳ度白细胞和血小板计数下降率分别为36.4%和21.8%。有4例患者因不良反应退出研究,其中1例患者因消化管出血而死亡,1例患者发生Ⅲ度血压升高而未得到控制,1例患者发生室上性心率失常,1例患者发生Ⅳ度肝功能异常。结论:恩度联合第3代含铂化疗方案治疗晚期NSCLC的近期CBR较高,PFS有所延长,不良反应尚能耐受。Objective：To observe the efficacy,median progression-free survival （PFS） and adverse reaction induced by rh-endostatin injection （Endostar） plus platin-based chemotherapy for advanced non-small cell lung cancer （NSCLC）.Methods：Fifty five histologically or cytologically confirmed advanced NSCLC patients received Endostar combined with platin-based chemotherapy for more than 2 cycles. The evaluated parameters included PFS,response rate （RR）,clinical benefit rate （CBR） and adverse reaction. Results：Of the 51 patients who can be evaluated for response,15 （29.4%） achieved partial response （PR）,27 （52.9%） had stable disease （SD）,9 （17.6%） had progressive disease（PD）,no patient had complete response（CR）. The overall RR was 29.4% （15/51） and CBR was 82.4% （42/51）. The median PFS was 6.3 months. There were no significant differences in the short-term efficacy and PFS between the patients who had different pathological features （P=0.037）,those had naive or relapsed diseases （P=0.101）,or those received different chemotherapeutic regimens （P=0.232）. The total white cells and platelets decreased by 72.7% and 54.5%,respectively. The frequency of grade Ⅲ or Ⅳ neutropenia and thrombocytopenia were 36.4% （20 caces） and 21.8% （12 cases）,respectively. Four patients stopped the therapy for adverse reaction. One died of gastrointestinal hemorrhage; one had uncontrolled grade Ⅲ hypertension; one had superventricular arrhythmia; one had grade Ⅳ hepatic dysfunction. Conclusion：The combination of Endostar and platin-based chemotherapy increased the CBR and prolonged the PFS of the patients with advanced NSCLC. The toxicities were tolerable.

关 键 词：癌 非小细胞肺 重组人血管内皮抑制素类 抗肿瘤联合化疗方案 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]